The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Dhub and others I hope you become a millionaire, just look after it. Remember you only need so much and making it and losing it is a bad bad feeling.
I remember watching Harry Redknapp talking about money and he said which is quite correct that as long as you can go to a cash machine when you want and take a couple of hundred quid out then you don’t really need much more.
My dad had a close friend who sold his pharmaceutical company in the 80’s for 30 million and they were walking around the harbour in Puerto Banus and a helicopter landed on the back of a yacht and he said to my dad that’s how the other half live!! 😂😂
GLA with your investments.
This isn’t a pop at anyone in particular but my pet hate is when people try and get rich quick with shares and invest in the most volatile market and when it goes tits up they kick off. The success of Penny share companies is extremely low, but this one will I believe be a massive success.
Honestly for an easier ride stick with FTSE100 companies.
Moorscloud I have always thought this big one would be released when Vlad is awake so he can see the response himself, I would want to be. It’s 2am in New York now so I think the RNS will be around the 2pm mark our time. But that’s just me.
*********MY POST AT 7:08*********
On reflection a good point has been raised here this is not new news this is from august and Vlads response when responding to the FDA I was reading the RNS’S and I just think this RNS snippet shows even more confidence that the minor issue will be lifted by the FDA.
Thanks Keving23
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are pleased that the FDA has agreed to our plan and preliminary test results to address their concerns regarding our HEMO-CAR-T IND application. We are now working hard to complete the schedule of work set out in the plan and to re-submit the IND as expeditiously as possible in order to move forward with clinical trials of HEMO-CAR-T."